The poor performance of apps assessing skin cancer risk

British Medical Journal 368 (8233) (2020)
Download Edit this record How to cite View on PhilPapers
Abstract
Over the past year, technology companies have made headlines claiming that their artificially intelligent (AI) products can outperform clinicians at diagnosing breast cancer, brain tumours, and diabetic retinopathy. Claims such as these have influenced policy makers, and AI now forms a key component of the national health strategies in England, the United States, and China. While it is positive to see healthcare systems embracing data analytics and machine learning, concerns remain about the efficacy, ethics, and safety of some commercial, AI health solutions. This paper argues that improved regulation and guidance is urgently required to mitigate risks, ensure transparency and best practice, Without this, patients, clinicians, and other stakeholders cannot be assured of an app’s efficacy, and safety.
Categories
No categories specified
(categorize this paper)
PhilPapers/Archive ID
MORTPP-13
Upload history
Archival date: 2021-06-09
View other versions
Added to PP index
2021-06-09

Total views
17 ( #59,591 of 2,432,759 )

Recent downloads (6 months)
17 ( #37,617 of 2,432,759 )

How can I increase my downloads?

Downloads since first upload
This graph includes both downloads from PhilArchive and clicks on external links on PhilPapers.